CLINICAL RESEARCH: MYOCARDIAL INFARCTION
Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction
Jorik R. Timmer, MD*,
Jan Paul Ottervanger, MD, PhD*,
Menko-Jan de Boer, MD, PhD, FACC*,
Jan-Henk E. Dambrink, MD, PhD*,
Jan C.A. Hoorntje, MD, PhD*,
A.T. Marcel Gosselink, MD, PhD*,
Harry Suryapranata, MD, PhD*,
Felix Zijlstra, MD, PhD, FACC ,
Arnoud W.J. van't Hof, MD, PhD*,* Zwolle Myocardial Infarction Study Group
* Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Zwolle, the Netherlands
Department of Cardiology, Thoraxcenter, University Hospital Groningen, Groningen, the Netherlands
Manuscript received October 27, 2004;
revised manuscript received December 2, 2004,
accepted December 13, 2004.
* Reprint requests and correspondence: Dr. Arnoud W. J. van't Hof, Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Groot Wezenland 20, 8011 JW Zwolle, the Netherlands
(Email: v.r.c.derks{at}isala.nl).
OBJECTIVES: This study was designed to investigate whether elevated glucose is associated with impaired Thrombolysis In Myocardial Infarction (TIMI) flow before primary percutaneous coronary intervention (PCI).
BACKGROUND: Reperfusion before primary PCI in patients with ST-segment elevation myocardial infarction (STEMI) is associated with an improved outcome. Hyperglycemia in patients with STEMI is associated with an adverse prognosis. Hyperglycemia may induce a pro-thrombotic state and therefore be of influence on TIMI flow before PCI.
METHODS: A total of 460 consecutive patients with STEMI treated with primary PCI were included in this analysis. Hyperglycemia was defined as a glucose 7.8 mmol/l (140 mg/dl).
RESULTS: Hyperglycemia was observed in 70% and TIMI flow grade 3 before primary PCI in 17% of the patients. Patients with hyperglycemia less often had TIMI flow grade 3 before primary PCI (12% vs. 28%, p < 0.001). After adjustment for differences in baseline variables, hyperglycemia was a strong predictor of absence of reperfusion before primary PCI (odds ratio 2.6, 95% confidence interval 1.5 to 4.5).
CONCLUSIONS: Hyperglycemia in patients with STEMI is an important predictor of impaired epicardial flow before reperfusion therapy has been initiated. Investigation of methods improving coronary flow before primary PCI in these patients is warranted.
|
Abbreviations and Acronyms
| | OR = odds ratio | | PCI = percutaneous coronary intervention | | STEMI = ST-segment elevation myocardial infarction | | TIMI = Thrombolysis In Myocardial Infarction |
|
This article has been cited by other articles:

|
 |

|
 |
 
K R Bainey, Y Fu, C B Granger, C W Hamm, D R Holmes Jr, W W O'Neill, R Seabra-Gomes, M E Pfisterer, F Van de Werf, P W Armstrong, et al.
Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients?
Heart,
August 15, 2009;
95(16):
1331 - 1336.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Anantharaman, M Heatley, and C F M Weston
Hyperglycaemia in acute coronary syndromes: risk-marker or therapeutic target?
Heart,
May 1, 2009;
95(9):
697 - 703.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Sinnaeve, P. G. Steg, K. A. A. Fox, F. Van de Werf, G. Montalescot, C. B. Granger, E. Knobel, F. A. Anderson, O. H. Dabbous, A. Avezum, et al.
Association of Elevated Fasting Glucose With Increased Short-term and 6-Month Mortality in ST-Segment Elevation and Non-ST-Segment Elevation Acute Coronary Syndromes: The Global Registry of Acute Coronary Events
Arch Intern Med,
February 23, 2009;
169(4):
402 - 409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Dandona, A. Chaudhuri, H. Ghanim, and P. Mohanty
Insulin as an anti-inflammatory and antiatherogenic modulator.
J. Am. Coll. Cardiol.,
February 3, 2009;
53(5 Suppl):
S14 - S20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Opie
Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia
Circulation,
April 29, 2008;
117(17):
2172 - 2177.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Deedwania, M. Kosiborod, E. Barrett, A. Ceriello, W. Isley, T. Mazzone, and P. Raskin
Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism
Circulation,
March 25, 2008;
117(12):
1610 - 1619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. W. Nesto and R. M. Lago
Glucose: A Biomarker in Acute Myocardial Infarction Ready for Prime Time?
Circulation,
February 26, 2008;
117(8):
990 - 992.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Verges, M. Zeller, G. Dentan, J.-C. Beer, Y. Laurent, L. Janin-Manificat, H. Makki, J. E. Wolf, Y. Cottin, and on behalf of the Observatoire des Infarctus de Cot
Impact of Fasting Glycemia on Short-Term Prognosis after Acute Myocardial Infarction
J. Clin. Endocrinol. Metab.,
June 1, 2007;
92(6):
2136 - 2140.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Zarich and R. W. Nesto
Implications and Treatment of Acute Hyperglycemia in the Setting of Acute Myocardial Infarction
Circulation,
May 8, 2007;
115(18):
e436 - e439.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z Kadri, N Danchin, L Vaur, Y Cottin, P Gueret, M Zeller, J-M Lablanche, D Blanchard, G Hanania, N Genes, et al.
Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study
Heart,
July 1, 2006;
92(7):
910 - 915.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. Collet and G. Montalescot
The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes
Diabetes and Vascular Disease Research,
October 1, 2005;
2(3):
136 - 143.
[Abstract]
[PDF]
|
 |
|
|